TP53 and neuroendocrine carcinoma: A study by Lavigne et al. using 2012 (4th edition) WHO terminology included 15 grade 3 cancers, with TP53 mutations identified in two “poorly-differentiated neuroendocrine carcinomas” and one grade 2 NET67.